Targeted nanoparticles of different origins are considered as new-generation diagnostic and therapeutic tools. However, there are no targeted drug formulations within the composition of nanoparticles approved by the FDA for use in the clinic, which is associated with the insufficient effectiveness of the developed candidates, the difficulties of their biotechnological production, and inadequate batch-to-batch reproducibility. Targeted protein self-assembling nanoparticles circumvent this problem since proteins are encoded in DNA and the final protein product is produced in only one possible way. We believe that the combination of the endless biomedical potential of protein carriers as nanoparticles and the standardized protein purification protocols will make significant progress in “magic bullet” creation possible, bringing modern biomedicine to a new level. In this review, we are focused on the currently existing platforms for targeted self-assembling protein nanoparticles based on transferrin, lactoferrin, casein, lumazine synthase, albumin, ferritin, and encapsulin proteins, as well as on proteins from magnetosomes and virus-like particles. The applications of these self-assembling proteins for targeted delivery in vitro and in vivo are thoroughly discussed, including bioimaging applications and different therapeutic approaches, such as chemotherapy, gene delivery, and photodynamic and photothermal therapy. A critical assessment of these protein platforms’ efficacy in biomedicine is provided and possible problems associated with their further development are described.

The extreme aggressiveness and lethality of many cancer types appeal to the problem of the development of new-generation treatment strategies based on smart materials with a mechanism of action that differs from standard treatment approaches. The targeted delivery of nanoparticles to specific cancer cell receptors is believed to be such a strategy; however, there are no targeted nano-drugs that have successfully completed clinical trials to date. To meet the challenge, we designed an alternative way to eliminate tumors in vivo. Here, we show for the first time that the targeting of lectin-equipped polymer nanoparticles to the glycosylation profile of cancer cells, followed by photodynamic therapy (PDT), is a promising strategy for the treatment of aggressive tumors. We synthesized polymer nanoparticles loaded with magnetite and a PDT agent, IR775 dye (mPLGA/IR775). The magnetite incorporation into the PLGA particle structure allows for the quantitative tracking of their accumulation in different organs and the performing of magnetic-assisted delivery, while IR775 makes fluorescent in vivo bioimaging as well as light-induced PDT possible, thus realizing the theranostics concept. To equip PLGA nanoparticles with targeting modality, the particles were conjugated with lectins of different origins, and the flow cytometry screening revealed that the most effective candidate for breast cancer cell labeling is ConA, a lectin from Canavalia ensiformis. In vivo experiments showed that after i.v. administration, mPLGA/IR775–ConA nanoparticles efficiently accumulated in the allograft tumors under the external magnetic field; produced a bright fluorescent signal for in vivo bioimaging; and led to 100% tumor growth inhibition after the single session of PDT, even for large solid tumors of more than 200 mm³ in BALB/c mice. The obtained results indicate that the mPLGA/IR775 nanostructure has great potential to become a highly effective oncotheranostic agent.

Background/Objectives: Nanoparticles have emerged as indispensable tools in modern biomedicine, enabling precise diagnostics, targeted therapy, and controlled drug delivery. Despite their rapid progress, the translation of nanoparticle-based systems critically depends on the ability to detect, quantify, and track them across complex biological environments. Over the past two decades, a wide spectrum of detection modalities has been developed, encompassing optical, magnetic, acoustic, nuclear, cytometric, and mass spectrometric principles. Yet, no comprehensive framework has been established to compare these methods in terms of sensitivity, spatial resolution, and clinical applicability. Methods: Here we show a systematic analysis of all broadly applicable nanoparticle detection strategies, outlining their mechanisms, advantages, and drawbacks, and providing illustrative examples of practical applications. Results: This comparison reveals that each modality occupies a distinct niche: optical methods offer high sensitivity but limited penetration depth; magnetic and acoustic modalities enable repeated non-invasive tracking; nuclear imaging ensures quantitative, whole-body visualization; and invasive biochemical or histological assays achieve ultimate detection limits at the cost of tissue integrity. These findings redefine how each technique contributes to nanoparticle biodistribution and mechanistic studies, clarifying which are best suited for translational and clinical use. Conclusions: Placed in a broader context, this review bridges fundamental nanotechnology with biomedical applications, outlining a unified methodological framework that will guide the rational design, validation, and clinical implementation of nanoparticle-based therapeutics and diagnostics. By synthesizing the field into a single comparative framework, it also provides an accessible entry point for newcomers in nanotechnology and related biomedical sciences.